VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9137 USD | +2.65% |
|
+52.28% | +27.43% |
| Apr. 23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
| Mar. 26 | Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024 |
Financials (USD)
| Sales 2024 * | 3.63M | Sales 2025 * | 16.48M | Capitalization | 73.05M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -32M | EV / Sales 2024 * | 17.7 x |
| Net cash position 2024 * | 8.9M | Net Debt 2025 * | 18.4M | EV / Sales 2025 * | 5.55 x |
| P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-2.76
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
More press releases
| 1 day | +2.65% | ||
| 1 week | +52.28% | ||
| Current month | +20.70% | ||
| 1 month | +22.97% | ||
| 3 months | -5.80% | ||
| 6 months | +13.50% | ||
| Current year | +27.43% |
1 week
0.59
1.02
1 month
0.571.02
Current year
0.571.23
1 year
0.552.10
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 21-01-31 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Martin Faulkes
CHM | Chairman | 80 | 11-10-05 |
Guy Innes
BRD | Director/Board Member | 67 | 11-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.8902 | +11.27% | 489,819 |
| 24-04-24 | 0.8 | -5.88% | 354,848 |
| 24-04-23 | 0.85 | +41.67% | 3,440,054 |
| 24-04-22 | 0.6 | -2.60% | 51,117 |
| 24-04-19 | 0.616 | -0.19% | 245,813 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8902
USD
Average target price
3.725
USD
Spread / Average Target
+318.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.43% | 73.05M | |
| -20.45% | 10.67B | |
| +43.17% | 3.22B | |
| -35.86% | 2.09B | |
| -17.21% | 2.04B | |
| -29.81% | 1.46B | |
| +17.56% | 1B | |
| -4.37% | 734M | |
| -37.00% | 391M | |
| -46.94% | 379M |
- Stock Market
- Equities
- VNRX Stock
